Peer-reviewed veterinary case report
Hormone receptor changes in dog mammary tumors and lymph node spread
By Ferreira, Tiago et al.·Published in Research in veterinary science·2025·University of Trá·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Hormone receptor discrepancy and molecular subtype changes in canine mammary carcinomas and synchronous lymph node metastasis.
- Species:
- dog
Plain-English summary
A female dog with a mammary tumor was found to have cancer that could spread to nearby lymph nodes. Researchers studied the tumor and the lymph nodes to see if there were differences in hormone receptors and molecular subtypes, which can affect treatment outcomes. They discovered that nearly half of the tumors had different characteristics compared to the lymph nodes, which could lead to treatment failures. This highlights the importance of checking both the primary tumor and any lymph node metastases to better understand the cancer and improve treatment plans.
People also search for: dog mammary tumor treatment · canine cancer lymph node metastasis · dog hormone receptor cancer
Abstract
Mammary tumors are the most prevalent neoplasms in intact female dogs; up to 50 % are considered malignant and have the potential to metastasize to regional lymph node and distant organs. Changes in tumor molecular subtype, including its receptor status, can occur during mammary tumor progression. This study aimed to explore hormone receptor discrepancies and the relationship between molecular subtypes in primary mammary tumors (PTs) and paired lymph node metastases (LNMs). Thirty PTs samples and paired LNMs were evaluated for estrogen receptor (ER), progesterone receptor (PR), human epidermal growth factor receptor 2 (HER2) and Ki-67 through immunohistochemistry. After analysis, the discordance rates were 11.1 %, 26.9 %, and 11.5 %, for ER, PR and Ki-67, respectively. All samples were negative for HER2. The molecular subtypes showed a 40.7 % discordance rate between PTs and matched LNMs. Additionally, 44.4 % of luminal A-like, 36.4 % of luminal B-like and 42.8 % of triple-negatives in PTs displayed different subtypes in the corresponding LNMs, respectively. Among discordant cases, five progressed to subtypes usually associated with a poor prognosis, while six presented a transition to subtypes frequently associated with a favorable prognosis. Discordance in molecular subtypes between PTs and LNMs may lead to therapeutic failures. Therefore, the assessment of molecular subtypes at both sites is crucial and could offer potential for the development of more accurate prognostic and treatment models.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/40730117/